Swedish pharmaceutical company Orexo AB (STO:ORX) (OTCQX:ORXOY) on Tuesday announced a collaboration with Abera Bioscience to develop nasal powder vaccines using Orexo's AmorphOX technology.
AmorphOX has the potential to improve the stability and efficacy of Abera's vaccine candidates, particularly for intranasal delivery.
The partnership aims to develop powder-based intranasal influenza vaccine candidates, leveraging Abera's innovative vaccine platform and Orexo's drug delivery technology.
The collaboration is funded by Abera through various grants, primarily from the Coalition for Epidemic Preparedness Innovation (CEPI).
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Zoetis announces EU approval for Portela to relieve osteoarthritis pain in cats
4basebio synthetic DNA used in Phase I/II mRNA therapy trial
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Sanofi reports data showing high-dose flu vaccine delivers superior protection for older adults
GC Biopharma granted CMO rights for Curevo Vaccine's shingles vaccine
TransCode acquires Polynoma and secures USD25m investment from CK Life Sciences
Wasatch BioLabs adds three Oxford Nanopore-developed research-use-only assays to service portfolio
GSK and IQVIA expand vaccine track with local data to drive targeted public health action